BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology PlansSeeking Alpha • 05/06/26
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?Zacks Investment Research • 04/22/26
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026GlobeNewsWire • 04/21/26
BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial CancerGlobeNewsWire • 04/11/26
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment strugglesReuters • 04/01/26
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next24/7 Wall Street • 03/30/26
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerGlobeNewsWire • 03/24/26
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 03/10/26
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focusProactive Investors • 03/10/26